ResearcherQueen's University BelfastActive in the last 2 years
Christopher J. Scott
Matched on ORCID iD 0000-0002-7582-3808; OpenAlex author ID A5005209374. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 5)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 10
2020: 3 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper
Papers 6
- Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors. Co-author DOI 10.1158/1078-0432.ccr-23-0131↗
- Antibody therapy in pancreatic cancer: mAb-ye we're onto something? Last author DOI 10.1016/j.bbcan.2021.188557↗
- Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance. Last author DOI 10.3390/cancers13246175↗
- DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. Last author DOI 10.1016/j.jconrel.2020.05.046↗
- Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant… Last author DOI 10.1038/s41416-020-01046-6↗
- Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an entrapped payload to pancreatic cancer ce… Last author DOI 10.1039/d0nr02387f↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michelle K. Greene · 5 shared papers, 2020–2024 · strength 0.71
- Paper Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance. DOI 10.3390/cancers13246175↗
- Paper Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors. DOI 10.1158/1078-0432.ccr-23-0131↗
- Paper Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an e… DOI 10.1039/d0nr02387f↗
- Robert M. Straubinger · 3 shared papers, 2020–2024 · strength 0.37
- Paper Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors. DOI 10.1158/1078-0432.ccr-23-0131↗
- Paper DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in … DOI 10.1016/j.jconrel.2020.05.046↗
- Paper Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate … DOI 10.1038/s41416-020-01046-6↗
- Michael C. Johnston · 2 shared papers, 2020–2021 · strength 0.31
- Paper Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance. DOI 10.3390/cancers13246175↗
- Paper DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in … DOI 10.1016/j.jconrel.2020.05.046↗
- Martin M. Clynes · 2 shared papers, 2020–2024 · strength 0.28
- Paper Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors. DOI 10.1158/1078-0432.ccr-23-0131↗
- Paper DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in … DOI 10.1016/j.jconrel.2020.05.046↗
- Tista Roy Chaudhuri · 1 shared paper, 2024 · strength 0.19
- Qingxiang Lin · 1 shared paper, 2024 · strength 0.19
- Wen Wee Ma · 1 shared paper, 2024 · strength 0.19
- Anna J. Boland · 1 shared paper, 2021 · strength 0.17
- Jun Wang · 1 shared paper, 2020 · strength 0.09
- Sandra Roche · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.